WALTHAM, MA–Viridian Therapeutics reported a net loss of $101.2 million for the third quarter of 2026, nearly three times the $34.6 million loss recorded a year earlier, as the biotechnology company expanded commercial operations following the launch of its thyroid eye disease treatment Lumvoa.
The Waltham, Massachusetts-based company reported $24.7 million in net product revenue from Lumvoa (veligrotug-vvze) during the quarter ended September 30, marking its first quarter of commercial sales for the treatment. More than 100 patients were receiving the therapy by the end of the quarter.
Total quarterly revenue was approximately $25.8 million, compared with $70.6 million in the same period last year, when revenue included a substantial licensing payment.
Viridian ended September with $955.2 million in cash, cash equivalents and marketable securities. The company said its existing financial resources, combined with anticipated revenue from Lumvoa and its investigational treatment elegrobart, if approved, are expected to support its current business plans through profitability.
“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. “These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization. We are excited about this early momentum and look forward to building on it as we continue to execute our launch strategy and strive to bring Lumvoa to more patients with TED. Our pipeline also continues to move forward as we advance elegrobart, our subcutaneously administered anti-IGF-1R, toward a planned BLA submission for TED in the first quarter of 2027. In addition, we look forward to several important milestones for the remainder of this year, including sharing clinical data for VRDN-008, development plans for our FcRn portfolio, and initiating a first-in-human clinical trial in patients for our TSHR program VRDN-292.”
Viridian’s research and development expenses declined to $70.1 million during the quarter from $86.3 million a year earlier. The decrease reflected lower spending on clinical studies involving veligrotug and elegrobart, partially offset by investments in additional drug development programs and higher personnel costs.
Selling, general and administrative expenses increased sharply to $57.6 million from $24.3 million in the corresponding quarter of 2025. The increase was primarily attributed to personnel expenses and professional services associated with the commercial launch of Lumvoa and the company’s expanding operations.
For the first nine months of 2026, Viridian reported a net loss of $333.2 million, compared with $222.2 million during the same period last year.
The company also reported progress in securing insurance coverage and reimbursement arrangements for Lumvoa. The Centers for Medicare & Medicaid Services assigned the treatment a permanent J-code, J3242, which will take effect January 1, 2027.
Viridian is simultaneously preparing to seek regulatory approval for elegrobart, another treatment being developed for thyroid eye disease.
The company expects to submit a Biologics License Application to the U.S. Food and Drug Administration during the first quarter of 2027.
If approved, elegrobart is expected to be available through an autoinjector that patients could use at home, with dosing schedules of every four or eight weeks.
Viridian said its existing commercial and medical operations supporting Lumvoa could also support an eventual elegrobart launch without requiring substantial additional investment.
Beyond thyroid eye disease, the company is advancing several experimental treatments targeting autoimmune disorders.
Its VRDN-292 program, which targets the thyroid-stimulating hormone receptor, remains on schedule to begin a Phase 1 clinical trial involving patients with Graves’ disease during the fourth quarter of 2026.
The investigational monoclonal antibody is being developed for subcutaneous administration, with the potential for extended intervals between doses.
Viridian is also developing treatments targeting the neonatal Fc receptor, known as FcRn, which plays a role in regulating antibody levels in the body.
One candidate, VRDN-006, demonstrated reductions in immunoglobulin G levels during a Phase 1 study involving healthy volunteers. The company reported that the treatment was generally well tolerated and did not substantially affect albumin or low-density lipoprotein levels.
Another candidate, VRDN-008, is a bispecific antibody designed to provide a longer duration of activity. In a preclinical study involving nonhuman primates, the treatment demonstrated a longer half-life and more sustained reductions in immunoglobulin G compared with efgartigimod.
Viridian expects to release Phase 1 clinical data for VRDN-008 and provide additional development plans for its FcRn drug portfolio before the end of 2026.
The company had approximately 125.6 million common shares outstanding on an as-converted basis as of September 30.
Viridian Therapeutics develops antibody-based medicines for autoimmune and rare diseases, with an initial commercial focus on thyroid eye disease. Its development pipeline includes investigational treatments targeting thyroid disorders and other immune-mediated conditions.


